Purpose. Patients with metabolic syndrome (MetS) have potentially higher risk for cardiovascular events. The aim of this study was to evaluate the effect of MetS on cardiac events in type-2 diabetic patients asymptomatic for coronary artery disease (CAD) in a Japanese population.
INTRODUCTION
Metabolic syndrome (MetS) is defined, by the combinations of diabetes mellitus, hypertension, dyslipidemia, central obesity, and microalbuminuria by the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III, and it is considered an important risk factor for future cardiovascular events. 1, 2 The Japanese Society for the Study of Obesity also used the MetS criteria of abdominal circumference, blood pressure C 130/85, triglyceride C 150 mg/dL or HDL cholesterol \ 40 mg/dL, and blood glucose C 110 mg/dL. In this metabolic status, cardiovascular event risk has been demonstrated to be higher with a hazard ratio (HR) in the range of 1.70-1.86 in a general Japanese population. 3, 4 Diabetes and chronic kidney disease were both significant risk factors for cardiovascular events in a Japanese prognostic cohort study (J-ACCESS study) using myocardial perfusion imaging (MPI). 5, 6 Subsequently, a J-ACCESS-2 study has been performed in Japan in patients with diabetes asymptomatic for coronary artery disease (CAD). 7, 8 No studies dealing with asymptomatic patients with MetS and its relationship to cardiovascular events in conjunction with MPI have been reported in Japan. Our hypothesis in this study was that MetS might increase the risk of cardiovascular events even in patients with diabetes who were asymptomatic for CAD. The significance of perfusion abnormalities in this study group was also examined.
METHODS

Subjects
J-ACCESS-2 prognostic databases involving 513 patients from 50 institutions with a follow-up period of 3 years were used. 7 The criteria for study inclusion included patients with type 2 diabetes, C50 years of age, a maximal carotid artery intimamedia thickness C 1.1 mm by ultrasonography or a urinary albumin excretion rate of C30 mg/g creatinine, or patients who satisfied at least two of the following four conditions: abdominal obesity with body mass index (BMI) C 25; and waist circumference C 85 cm for men and C90 cm for women; hypo-high density lipoprotein (HDL)-cholesterolemia (\40 mg/dl); hypertriglyceridemia (C150 mg/dl); and hypertension (blood pressure C 130/85 mmHg). Exclusion criteria included patients with myocardial infarction, effort angina, unstable angina, and those with abnormal electrocardiographic findings of ST depression [ 1 mm, multifocal premature ventricular contractions, tachyarrhythmias, and atrial fibrillation. Also excluded were patients with a hemoglobin A1c (HbA1c) C 10% or a serum creatinine C 1.5 mg/dL, valvular heart disease, idiopathicdilated cardiomyopathy, New York Heart Association class III or IV heart failure at the time of MPI, and arteriosclerosis obliterans of the lower extremities (with intermittent claudication, resting pain, and ulceration).
An institutional review board or committee approved the study in all institutions, and written informed consent was obtained from all subjects.
Definition of Metabolic Syndrome
In this subanalysis of the J-ACCESS-2 investigation, the criteria of MetS were determined by three or more of the following conditions: (1) BMI C 25 kg/m 2 ; (2) dyslipidemia (triglyceride C 150 mg/dL, HDL cholesterol B 40 mg/dL, or medication for dyslipidemia), (2) hypertension (systolic pressure C 130 mmHg, diastolic pressure C 85 mmHg or medication for hypertension); and (3) diabetes (fasting blood sugar C 110 mg/dL, or medications or insulin therapy for diabetes). Abdominal circumference criteria were not used in this subanalysis. 9 
Myocardial Perfusion Imaging
Stress-rest MPI was performed with 99m Tc-tetrofosmin. Exercise (71%) or pharmacological stress (29%) with dipyridamole, adenosine, or adenosine triphosphate was performed. The average dose of 99m Tc-tetrofosmin administered was 331 MBq for the initial study and 748 MBq for the second study. MPI data acquisition was performed with standard protocols, and a gated study was performed at least at resting condition. Myocardial short-axis, vertical long-axis, and horizontal long-axis images were generated and interpreted using a 20-segment model. Segmental myocardial defects were visually scored using a five-point scoring system: 0 = normal, 1 = mildly reduced, 2 = moderately reduced, 3 = severely reduced, and 4 = absent. Total defect scores were calculated as the sum of stress, rest, and difference scores (SSS, SRS, and SDS), respectively. Four SSS severity categories were used for risk-based groups of 0-3 (normal), 4-8 (mild), 9-13 (moderate), and C14 (severe). Quantification of the gated SPECT images was performed using quantitative gated MPI analysis (QGS) software (Cedars Sinai Medical Center, Los Angeles, CA, USA) at each institution. The left ventricular ejection fraction (LVEF, %), end-diastolic volume (EDV, mL), and end-systolic volume (ESV, mL) were calculated.
Coronary angiography was performed in 48 patients after MPI, and a significant coronary artery stenosis was observed in 11 patients with MetS and 14 with non-MetS. Multi-vessel CAD was observed in four patients with MetS and eight with non-MetS (P = .93 for number of coronary artery stenosis between MetS and non-MetS groups).
Definition of Events and Follow-up
The cardiovascular and cerebrovascular events were investigated each year after the registration. After excluding patients who had early revascularization within 30 days after registration (n = 7), noncardiac death (n = 7), and patients lost during follow-up (n = 14), a total of 485 patients were selected for prognostic analysis. Events of cardiac death, sudden death (natural, rapid, and unexpected death from cardiac causes: witnessed cardiac arrest or death \1 hour after the onset, or unwitnessed deaths within 24 hours after the patients were last seen to be alive), and nonfatal acute coronary syndrome (ACS) were defined as hard events. Total cardiovascular events further included percutaneous coronary intervention (PCI), coronary artery bypass grafting, de novo-diagnosed stable angina, unstable angina, and severe heart failure requiring hospitalization. Other vascular-related events such as transient ischemic attack of the brain, stroke, and de novo-diagnosed peripheral vascular disease with intermittent claudication, resting pain and ulceration were also included in the total events.
Statistics
Continuous variables are expressed as mean ± standard deviation. We applied the Wilcoxon rank sum test to compare the results from patients with and without cardiovascular events and the Chi-square test to categorical data. The univariate Cox proportional hazard model was used to evaluate each variable. The dependent variable included the occurrence of total events, cardiovascular events, and death. The relative HRs and 95% confidence of interval (CI) were calculated. The multivariate Cox proportional model was applied based on statistically significant independent variables. Kaplan-Meier analysis was also performed to analyze survival curves. Statistical significance was defined as P \ .05.
RESULTS
Comparison of Groups Between MetS and Non-MetS Groups
Based on the definition of MetS, 229 patients were classified into the MetS group and 256 into the non-MetS group (Table 1 ). The MetS group had a higher BMI and larger abdominal circumference than the non-MetS group.
With respect to dyslipidemia, HDL cholesterol was lower in the MetS group, but low-density lipoprotein (LDL) cholesterol was comparable between both groups. Gated SPECT showed that the EDV and ESV were higher in the MetS group than in the non-MetS group. However, the degree of abnormal perfusion as determined by SSS or SDS, and resting perfusion defects by SRS, was similar between MetS and non-MetS groups. During the follow up of three years, 14 cardiovascular hard events occurred. The event rates of cardiac death and cardiovascular events did not differ significantly between the two groups. When the breakdown of total events other than death was observed, cardiac disease-related events totaled 11 for MetS and 19 for non-MetS groups, cerebrovascular events numbered 15 for MetS and 6 for non-MetS groups, and peripheral vascular disease-related events totaled 3 for MetS and 3 for non-MetS groups (Pearson test, P = .103). 
Cox Proportional Hazard Analysis
Based on univariate Cox proportional hazard analysis, significant variables related to total events included age, current smoking, insulin use, total cholesterol, LVEF, SSS C 9, and SDS C 2 (Table 2) . However, to predict cardiovascular hard events, only insulin and blood urea nitrogen were significant, and SSS, SDS, and eGFR were not significant. For hard events, the multivariate analysis could not be performed because of a relatively low incidence of hard events. For total events, multivariate analysis showed no additional variables to the SSS C 9. Coronary artery stenosis documented during the course of follow-up was analyzed by the univariate analysis. The hazard ratio of the presence of coronary artery stenosis for total events was 4.63 (P \ .0001), and that for cardiovascular hard events was 3.57 (P = .096).
MetS as a Predictor of Events
To evaluate the role of variables related to MetS, the presence of MetS and the number of items for MetS were included for Cox proportional hazard analysis (Table 3) .
However, the variables of MetS were not significantly related to cardiac death and total events. In contrast, SSS C 9 and SDS C 2 were significantly related to total events (HR = 2.32 for SSS and 3.45 for SDS).
Differences in Medication
When the MetS and non-MetS groups were compared, the MetS group had higher incidences of biguanide (23.1% vs 14.1%, P \ .0138), angiotensin II antagonist (45.1% vs 30.1%, 0.0010), calcium channel blocker (53.7% vs 32.8%, P \ .0001), alfa blocker (8.3% vs 2.3%, P = .0059), and lower incidence of aspirin (15.7% vs 25.8%, P = .0093). No statistical differences were found between the two groups in terms of medication of sulfonylurea (47.2% vs 43.0%, P = .40), statin (38.4% vs 31.6%, P = .14) and insulin use (27.1% vs 32.4%, P = .24).
Survival Analysis
Kaplan-Meier survival analysis was performed in patients with SSS B 9 and [9, and with and without Higher SSS has significant impact on the total event rate, but not on mortality.
MetS (Figure 1 ). When all events were analyzed, the SSS C 9 group showed higher incidence of total events, but cardiovascular events including cardiac death, sudden death and ACS did not reach statistical significance when both groups were compared. Patients with and without MetS did not show significant differences in total event analysis. When patients were classified based on SSS and MetS, the groups differed significantly. However, the contribution of SSS was more significant as shown in Figure 1D .
DISCUSSION
MetS is an important predictor of cardiovascular events. In asymptomatic patients with diabetes, however, the effects of additional factors of MetS on cardiovascular events have not been clarified. In this subanalysis based on J-ACCESS-2 databases, we classified patients into MetS and non-MetS groups and found that the only factor related to total cardiovascular events was myocardial perfusion abnormalities at stress or ischemia, and MetS was not a significant predictor in this study population. Cardiovascular events and ischemia were as commonly observed in diabetic patients without MetS as in the case in those with MetS.
The J-ACCESS-2 investigation was a multicenter prognostic investigation involving asymptomatic type 2 diabetes. 8 The selection criteria included abdominal circumference, BMI, hypertension, and dyslipidemia. The MetS criteria were satisfied in approximately half of the asymptomatic patients. The total event rate was observed in 13% of the patients, although the cardiac death rate was relatively small. Multivariate Cox proportional hazard analysis showed that significant variables for total cardiovascular events comprised stress perfusion defect (SSS C 9), a low eGFR, and being a current smoker. We therefore tried to clarify the contribution of MetS to occurrence of cardiovascular events, since a non-invasive stress test is sometimes indicated even in asymptomatic populations of MetS. However, although the MetS group showed a higher incidence of abnormalities for dyslipidemia, hypertension and eGFR as well as larger ventricular volumes than the non-MetS group, no difference was observed between the two groups with respect to total and hard cardiovascular event rates.
There was no difference in any of the MPI variables between the MetS and no Mets groups. This was probably caused by the therapeutic effects for ischemia including PCI and medication, which resulted in reduction of hard cardiovascular events. It should be noted that an MPI abnormality was related to total events, including cerebrovascular and peripheral vascular events. An MPI abnormality cannot directly be used as a predictor for non-cardiac events. However, cerebrovascular events are the third highest cause of mortality in Japan, and diabetes, dyslipidemia, and hypertension, in addition to advanced age, are major characteristics commonly associated with the total events in this study. Considering these characteristics, the higher total event rate in patients with an abnormal MPI might be explained.
A study in the United States using 7,849 patients from a multicenter prospective registry analyzed the importance of MetS for predicting cardiovascular events. 10 There was an additive value in predicting major cardiac events using the number of risk factors for MetS and the extent and severity of abnormalities in MPI. Patients with five risk factors of MetS were of particularly high risk showing hazard ratios from 7.8 to 14.1-fold for mild to severely abnormal MPI findings. Acampa et al showed that in the IDIS multicenter prospective study in diabetic patients, addition of MPI data to a prediction model based on traditional risk factors and ECG stress test data significantly improved coronary heart disease risk classification. 11 In a Japanese study involving 1,424 type 2 diabetic patients, a high prevalence (38-53%, depending on sex and definition) of MetS was found among diabetic patients. 12 Although coronary heart disease events were observed in 4.4% during an 8-year study, the individual components of MetS, such as hyperlipidemia or hypertension, were equivalent or better predictors than the definition of MetS in men. The present study did not confirm the significance of MetS for major cardiovascular events. This was probably due to selection bias during the J-ACCESS-2 investigation, as cardiac death and cardiovascular hard event rates were in 1.2% and 2.9% per 3 years, respectively. Another factor contributing to the equivalent event rate was the effect of more active medications in the MetS group, which presumably improved their metabolic status and reduced mortality. Therefore, in the group with a low-risk profile for CAD and medically treated patients as in the J-ACCESS-2 study, MetS was not a major predictor of cardiac events.
A subanalysis was performed to see whether the presence of MetS had significant effects on screening in patients with type 2 diabetes. The effectiveness of screening by MPI in asymptomatic diabetic patients was investigated in a DIAD study. 13 It was found that cardiac event rates were low and were not significantly reduced by MPI screening for myocardial ischemia over a 4.8-year period. However, the positive predictive value of having moderate or large MPI defects was 12%. Although screening all patients with diabetes is not justified, restricting screening to a patient population in which a relatively high positive yield can be ensured would be a practical approach. 14, 15 In fact, the variable of a SSS C 9 was associated with a high total event rate in this study. Based on the MPI stress abnormality, optimal medical therapy and/or PCI would be indicated for those patients, which might subsequently result in improved patient outcome. The selection criteria for further non-invasive stress testing might include typical anginal chest pain, ischemic electrocardiographic abnormalities with treadmill exercise, high coronary calcium scoring, etc. as evidenced by nuclear cardiology guidelines in the USA and Japan. 16, 17 Coronary artery calcium scoring was not included in this study. Some of the patients with minimal or absent coronary calcification might have been excluded, and those with increased atherosclerotic burden would have been eligible for MPI. 18 As the impact of MPI and MetS may also differ among ethnic backgrounds, an optimal test in symptomatic and non-symptomatic patients for CAD should be further investigated in various populations.
LIMITATIONS
A larger number of subjects or a longer follow-up period are required to better analyze the hard cardiac events. As only asymptomatic patients were included in this study, a comparative risk group study may be indicated by including symptomatic patients or those with moderate likelihood of CAD. The selection criteria for MetS used BMI C 25, which was lower than the criteria of WHO using C30, but it has been noted that Japanese patients with type 2 diabetes are not obese compared with American and some European populations. 19 Although patients with type 1 diabetes appear to have greater risk of cardiac death than other patients based on any MPI result, we included only type 2 diabetes in this study. 20 
CONCLUSION
In patients with type 2 diabetes, though asymptomatic for CAD, the presence of MetS did not increase the rate of hard and total cardiac events. Cardiovascular event rates are similar in diabetic patients without MetS and those with MetS. However, a SSS C 9 was associated with a high incidence of total cardiovascular events. Therefore, routine screening by MPI in asymptomatic patients fulfilling MetS criteria is not indicated, but potentially higher-risk asymptomatic diabetic population who might benefit from MPI should be further investigated.
